Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 145.27 USD 0.55% Market Closed
Market Cap: 349.8B USD
Have any thoughts about
Johnson & Johnson?
Write Note
Section:
 

Relative Value

The Relative Value of one JNJ stock under the Base Case scenario is 175.9 USD. Compared to the current market price of 145.27 USD, Johnson & Johnson is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JNJ Relative Value
Base Case
175.9 USD
Undervaluation 17%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4
P/S
P/S
Price to Sales
4
vs History
92
vs Industry
30
Median 3Y
4.8
Median 5Y
4.5
Industry
2.5
Forward
3.9
More Details
23.8
P/E
P/E
Price to Earnings
23.8
vs History
23
vs Industry
37
Median 3Y
22
Median 5Y
22.1
Industry
21.8
Forward
14.5
More Details
13.9
P/OCF
P/OCF
Price to OCF
13.9
vs History
92
vs Industry
26
Median 3Y
17.4
Median 5Y
16.3
Industry
16.1
More Details
12
P/FCFE
P/FCFE
Price to FCFE
12
vs History
93
vs Industry
11
Median 3Y
19.6
Median 5Y
17.4
Industry
23.8
More Details
5
P/B
P/B
Price to Book Value
5
vs History
93
vs Industry
14
Median 3Y
5.5
Median 5Y
5.6
Industry
2.1
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
90
vs Industry
27
Median 3Y
4.9
Median 5Y
4.6
Industry
2.7
Forward
4
More Details
6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6
vs History
93
vs Industry
33
Median 3Y
7.1
Median 5Y
6.7
Industry
5.2
More Details
11.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.5
vs History
93
vs Industry
31
Median 3Y
13.1
Median 5Y
13.5
Industry
13.5
Forward
11.7
More Details
15
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15
vs History
93
vs Industry
28
Median 3Y
17
Median 5Y
18.2
Industry
16.8
Forward
13.3
More Details
14.4
EV/OCF
EV/OCF
Enterprise Value to OCF
14.4
vs History
92
vs Industry
26
Median 3Y
17.4
Median 5Y
16.6
Industry
15.2
More Details
17.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.5
vs History
88
vs Industry
20
Median 3Y
21.3
Median 5Y
19.6
Industry
19.3
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
95
vs Industry
28
Median 3Y
2.8
Median 5Y
2.8
Industry
1.9
More Details

Multiples Across Competitors

JNJ Competitors Multiples
Johnson & Johnson Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.4 168.9 253.1
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
IE
Endo International PLC
LSE:0Y5F
147.1B USD 63.5 -50.3 236.2 592.2
P/S Multiple
Revenue Growth P/S to Growth
US
Johnson & Johnson
NYSE:JNJ
Average P/S: 382 947.7
4
13%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
IE
E
Endo International PLC
LSE:0Y5F
63.5
N/A N/A
P/E Multiple
Earnings Growth P/E to Growth
US
Johnson & Johnson
NYSE:JNJ
Average P/E: 32.4
23.8
-23%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -50.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBITDA: 437.2
11.5
14%
0.8
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
IE
E
Endo International PLC
LSE:0Y5F
236.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBIT: 1 869.3
15
28%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

See Also

Summary
JNJ intrinsic value, competitors valuation, and company profile.
DCF Valuation
JNJ stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JNJ stock valuation using valuation multiples.
Wall Street Estimates
JNJ price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JNJ stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.